カテゴリ： GlobalData, アメリカ, 企業調査

Cancer Genetics Inc (CGIX)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Cancer Genetics Inc (CGIX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8179
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：64
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Cancer Genetics Inc (CGI) is a pharmaceutical company that provides diagnostics products and services in oncology areas. The company offers products such as CGH microarrays, next-generation sequencing and DNA-FISH Probes. Its oncology tests and laboratory services offer critical genomic information to healthcare professionals, biopharma companies, and cancer centers. CGI provides clinical services such as expand DX, test menu, complete program, and summation report. The company offers a range of pharmacogenomics testing services for clinical oncologists, cancer centers, and research institutions, and for biotech and biopharma customers. It works in research collaboration with cancer centers to develop and validate proprietary tests. CGI is headquartered in Rutherford, New Jersey, the US.

Cancer Genetics Inc (CGIX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cancer Genetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cancer Genetics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
PierianDx Enters into Agreement with Cancer Genetics 13
Cancer Genetics Enters into Partnership with Indian Cooperative Oncology Network 14
Gentris to Enter into Agreement with Shanghai Institutes of Preventive Medicine 15
Cancer Genetics Enters into Agreement with Lantern Pharma 16
Cancer Genetics Enters into Agreement with Biotech and Pharma Companies 17
Cancer Genetics Enters into Agreement with BeiGene 18
Cancer Genetics Enters into Co-Marketing Agreement with Bio Analytical Research 19
Cancer Genetics Partners with H3 Biomedicine 20
Cancer Genetics Enters into Co-Development Agreement with Columbia University Medical Center 21
Mayo Clinic Forms Joint Venture With Cancer Genetics 22
Cancer Genetics Enters Into Agreement With Gilead Sciences To Provide Clinical Trial Services 24
Gentris Enters Into Co-Development With Shanghai Institutes of Preventive Medicine 25
Merger 26
NovellusDx to Merge with Cancer Genetics 26
Licensing Agreements 28
Cancer Genetics Enters into Licensing Agreement with Cleveland Clinic Foundation 28
Equity Offering 29
Cancer Genetics Prices USD7 Million in Private Placement of Units 29
Cancer Genetics Raises USD3 Million in First Tranche of Private Placement of Shares 30
Cancer Genetics to Raise USD5.5 Million in Private Placement of Shares and Warrants 31
Cancer Genetics Raises USD5 Million in Private Placement of Shares and Warrants 32
Cancer Genetics Raises USD12 Million in Public Offering of Shares 33
Debt Offering 35
Cancer Genetics Raises USD2.6 Million in Private Placement of 10% Notes Due 2019 35
Acquisition 36
ReproCELL Acquires BioServe Biotech from Cancer Genetics for USD1.9 Million 36
Cancer Genetics to Acquire vivoPharm for USD12 Million 37
Cancer Genetics Acquires Gentris for USD4.75 Million 38
Cancer Genetics Inc – Key Competitors 39
Cancer Genetics Inc – Key Employees 40
Cancer Genetics Inc – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Joint Venture 42
Recent Developments 43
Strategy And Business Planning 43
Sep 20, 2018: Cancer Genetics and NovellusDx agree to merge 43
Financial Announcements 44
Aug 14, 2018: Cancer Genetics announces second quarter 2018 financial results 44
May 15, 2018: Cancer Genetics Reports First Quarter 2018 Financial Results and Provides Strategic Business Updates 46
Apr 02, 2018: Cancer Genetics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Strategic Business Updates 48
Nov 09, 2017: Cancer Genetics Reports Record Third Quarter 2017 Revenue and 134% Increase in Contracted Bookings from Major Biotech and Pharmaceutical Companies 50
Aug 14, 2017: Cancer Genetics Announces Second Quarter 2017 Financial Results, Accretive Acquisition and Capital Raise 52
May 11, 2017: Cancer Genetics Announces 15% Revenue Increase in First Quarter of 2017 over 2016 on Strong Organic Growth While Continuing on Path to Profitability 54
Mar 23, 2017: Cancer Genetics Announces Record Revenue for Fourth Quarter and Full-Year 2016 and Provides 2017 Business Update 56
Corporate Communications 58
Jun 12, 2018: Cancer Genetics Appoints Michael McCartney As Chief Commercial Officer 58
Feb 05, 2018: Cancer Genetics Announces Resignation Of Panna Sharma As Chief Executive Officer 59
Nov 27, 2017: Cancer Genetics Appoints Renowned Biotech Entrepreneur Dr. Thomas F. Widmann to its Board of Directors 60
Legal and Regulatory 61
May 06, 2018: Kaskela Law: Shareholder Class Action Filed Against Cancer Genetics 61
Product News 62
Dec 11, 2017: Cancer Genetics Advances Understanding of Immune Response and Measurement in Lymphomas by Combining PD-L1 Expression Analysis With RNA Analysis 62
Other Significant Developments 63
Jan 06, 2017: Cancer Genetics Announces Consolidation and Cost Reduction in Administrative and Operational Support Functions 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64

List of Tables
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cancer Genetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cancer Genetics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Cancer Genetics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
PierianDx Enters into Agreement with Cancer Genetics 13
Cancer Genetics Enters into Partnership with Indian Cooperative Oncology Network 14
Gentris to Enter into Agreement with Shanghai Institutes of Preventive Medicine 15
Cancer Genetics Enters into Agreement with Lantern Pharma 16
Cancer Genetics Enters into Agreement with Biotech and Pharma Companies 17
Cancer Genetics Enters into Agreement with BeiGene 18
Cancer Genetics Enters into Co-Marketing Agreement with Bio Analytical Research 19
Cancer Genetics Partners with H3 Biomedicine 20
Cancer Genetics Enters into Co-Development Agreement with Columbia University Medical Center 21
Mayo Clinic Forms Joint Venture With Cancer Genetics 22
Cancer Genetics Enters Into Agreement With Gilead Sciences To Provide Clinical Trial Services 24
Gentris Enters Into Co-Development With Shanghai Institutes of Preventive Medicine 25
NovellusDx to Merge with Cancer Genetics 26
Cancer Genetics Enters into Licensing Agreement with Cleveland Clinic Foundation 28
Cancer Genetics Prices USD7 Million in Private Placement of Units 29
Cancer Genetics Raises USD3 Million in First Tranche of Private Placement of Shares 30
Cancer Genetics to Raise USD5.5 Million in Private Placement of Shares and Warrants 31
Cancer Genetics Raises USD5 Million in Private Placement of Shares and Warrants 32
Cancer Genetics Raises USD12 Million in Public Offering of Shares 33
Cancer Genetics Raises USD2.6 Million in Private Placement of 10% Notes Due 2019 35
ReproCELL Acquires BioServe Biotech from Cancer Genetics for USD1.9 Million 36
Cancer Genetics to Acquire vivoPharm for USD12 Million 37
Cancer Genetics Acquires Gentris for USD4.75 Million 38
Cancer Genetics Inc, Key Competitors 39
Cancer Genetics Inc, Key Employees 40
Cancer Genetics Inc, Other Locations 41
Cancer Genetics Inc, Subsidiaries 41
Cancer Genetics Inc, Joint Venture 42

List of Figures
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cancer Genetics Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Cancer Genetics Inc (CGIX)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Benvenue Medical, Inc.：医療機器：M&Aディール及び事業提携情報
    Summary Benvenue Medical, Inc (Benvenue Medical) is a manufacturer, designer and distributor of minimally invasive systems and other medical devices. The product portfolio of the company includes Luna, a 3D interbody fusion system designed for the treatment to restore disc height. Blazer, is a verte …
  • Institut Curie-製薬・医療分野：企業M&A・提携分析
    Summary Institut Curie is a cancer research foundation that operates cancer research institutes and hospitals and concentrates on the developing new treatments for cancer. The foundation carries out research in the areas of immunology, pharmachemistry, bioinformatics and systems biology, cell biolog …
  • Tecan Group Ltd (TECN)：製薬・医療：M&Aディール及び事業提携情報
    Summary Tecan Group Ltd (Tecan) is a provider of automated laboratory instruments and solutions for use in basic and translational research, clinical diagnostics, and drug discovery. The company develops, manufactures, and markets automated workflow solutions for laboratories and instrumentation sup …
  • Baker Hughes Incorporated (BHGE)-石油・ガス分野：企業M&A・提携分析
    Summary Baker Hughes Incorporated (Baker Hughes), a subsidiary of General Electric Co is a provider of oil and gas equipment and services. The company is a supplier of oilfield services, products, technology and systems to oil and gas industry. It also offers industrial and other products and servic …
  • Rutherford Electric Membership Corp：企業の戦略的SWOT分析
    Rutherford Electric Membership Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • VeriSign Inc (VRSN)：企業の財務・戦略的SWOT分析
    VeriSign Inc (VRSN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • DSW Inc.：戦略・SWOT・企業財務分析
    DSW Inc. - Strategy, SWOT and Corporate Finance Report Summary DSW Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Protea Biosciences Group Inc：医療機器：M&Aディール及び事業提携情報
    Summary Protea Biosciences Group Inc (Protea) is a biotechnology company that develops mass spectometry solutions. The company offers technology for identification, characterization, and quantitation of biologically-important molecules for pharmaceutical development, research, and diagnostic applica …
  • Blue Dolphin Energy Co (BDCO)：企業の財務・戦略的SWOT分析
    Summary Blue Dolphin Energy Co (Blue Dolphin) operates as an oil and gas company that refines and markets petroleum products. The company own and operate pipeline assets and have leasehold interests in oil and gas properties. It also acquires, develops and explores oil and gas properties. Blue Dolph …
  • BioDiem Ltd-製薬・医療分野：企業M&A・提携分析
    Summary BioDiem Ltd (BioDiem) is a biotechnology company that focuses on developing and commercializing vaccines and infectious disease therapies. It develops vaccines and novel therapeutic candidates for the treatment of seasonal and pandemic influenza, antimicrobial and antifungal, and retinal dis …
  • Anglo American South Africa Limited：企業の戦略・SWOT・財務情報
    Anglo American South Africa Limited - Strategy, SWOT and Corporate Finance Report Summary Anglo American South Africa Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Medrobotics Corp：企業の製品パイプライン分析2018
    Summary Medrobotics Corp (Medrobotics), formerly Cardioborobotics Inc, is a medical device company that manufactures and markets flexible robot platforms. The company provides Flex robotic system, a robot-assisted surgical platform that offers physicians with single-site access while operating in ha …
  • Tredegar Corp (TG)：企業の財務・戦略的SWOT分析
    Tredegar Corp (TG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Oi S.A.：企業の戦略・SWOT・財務情報
    Oi S.A. - Strategy, SWOT and Corporate Finance Report Summary Oi S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • ITT Inc.：企業のM&A・事業提携・投資動向
    ITT Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ITT Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • Major Drilling Group International Inc (MDI)：企業の財務・戦略的SWOT分析
    Major Drilling Group International Inc (MDI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • Guangshen Railway Company Limited：戦略・SWOT・企業財務分析
    Guangshen Railway Company Limited - Strategy, SWOT and Corporate Finance Report Summary Guangshen Railway Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • China National Offshore Oil Corp：石油・ガス：M&Aディール及び事業提携情報
    Summary China National Offshore Oil Corp (CNOOC) carries out exploration, development, and production of crude oil and natural gas. The company also offers engineering and technical services, including oilfield, offshore oil engineering, and professional services. It is also involved in the producti …
  • Accugenomics Inc：医療機器：M&Aディール及び事業提携情報
    Summary Accugenomics Inc (Accugenomics) is a developer of oncology molecular diagnostics. The company develops and markets gene expression tests to diagnose and monitor cancer treatment. It offers gene expression tests including lung cancer risk test, standardized BCR-ABL molecular diagnostics test …
  • Oge Energy Corp：企業の戦略・SWOT・財務分析
    Oge Energy Corp - Strategy, SWOT and Corporate Finance Report Summary Oge Energy Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆